{"id":4920,"date":"2018-02-13T10:12:32","date_gmt":"2018-02-13T09:12:32","guid":{"rendered":"http:\/\/www.seventure.fr\/wp-content\/uploads\/2018\/02\/Seventure-Partners-Life-Sciences-Investing-Update-H2-2017_VF.pdf"},"modified":"2018-02-13T10:12:32","modified_gmt":"2018-02-13T09:12:32","slug":"seventure-partners-life-sciences-investing-update-h2-2017_vf","status":"inherit","type":"attachment","link":"https:\/\/www.seventure.fr\/en\/maat-pharma-launches-european-clinical-trial-in-severe-acute-graft-versus-host-disease-for-patients-receiving-allogeneic-hematopoietic-stem-cell-transplantation\/seventure-partners-life-sciences-investing-update-h2-2017_vf\/","title":{"rendered":"Seventure Partners Life Sciences Investing Update &#8211; H2 2017_VF"},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false},"class_list":["post-4920","attachment","type-attachment","status-inherit","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Seventure Partners Life Sciences Investing Update - H2 2017_VF | Seventure<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2018\/02\/Seventure-Partners-Life-Sciences-Investing-Update-H2-2017_VF.pdf\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2018\/02\/Seventure-Partners-Life-Sciences-Investing-Update-H2-2017_VF.pdf\",\"url\":\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2018\/02\/Seventure-Partners-Life-Sciences-Investing-Update-H2-2017_VF.pdf\",\"name\":\"Seventure Partners Life Sciences Investing Update - H2 2017_VF | Seventure\",\"isPartOf\":{\"@id\":\"https:\/\/www.seventure.fr\/en\/#website\"},\"datePublished\":\"2018-02-13T09:12:32+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2018\/02\/Seventure-Partners-Life-Sciences-Investing-Update-H2-2017_VF.pdf#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2018\/02\/Seventure-Partners-Life-Sciences-Investing-Update-H2-2017_VF.pdf\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2018\/02\/Seventure-Partners-Life-Sciences-Investing-Update-H2-2017_VF.pdf#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.seventure.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MaaT Pharma Launches European Clinical Trial in Severe Acute Graft-versus-Host Disease for patients receiving allogeneic Hematopoietic Stem Cell Transplantation\",\"item\":\"https:\/\/www.seventure.fr\/en\/maat-pharma-launches-european-clinical-trial-in-severe-acute-graft-versus-host-disease-for-patients-receiving-allogeneic-hematopoietic-stem-cell-transplantation\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Seventure Partners Life Sciences Investing Update &#8211; H2 2017_VF\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.seventure.fr\/en\/#website\",\"url\":\"https:\/\/www.seventure.fr\/en\/\",\"name\":\"Seventure\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.seventure.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Seventure Partners Life Sciences Investing Update - H2 2017_VF | Seventure","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2018\/02\/Seventure-Partners-Life-Sciences-Investing-Update-H2-2017_VF.pdf","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2018\/02\/Seventure-Partners-Life-Sciences-Investing-Update-H2-2017_VF.pdf","url":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2018\/02\/Seventure-Partners-Life-Sciences-Investing-Update-H2-2017_VF.pdf","name":"Seventure Partners Life Sciences Investing Update - H2 2017_VF | Seventure","isPartOf":{"@id":"https:\/\/www.seventure.fr\/en\/#website"},"datePublished":"2018-02-13T09:12:32+00:00","breadcrumb":{"@id":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2018\/02\/Seventure-Partners-Life-Sciences-Investing-Update-H2-2017_VF.pdf#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.seventure.fr\/wp-content\/uploads\/2018\/02\/Seventure-Partners-Life-Sciences-Investing-Update-H2-2017_VF.pdf"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2018\/02\/Seventure-Partners-Life-Sciences-Investing-Update-H2-2017_VF.pdf#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.seventure.fr\/en\/"},{"@type":"ListItem","position":2,"name":"MaaT Pharma Launches European Clinical Trial in Severe Acute Graft-versus-Host Disease for patients receiving allogeneic Hematopoietic Stem Cell Transplantation","item":"https:\/\/www.seventure.fr\/en\/maat-pharma-launches-european-clinical-trial-in-severe-acute-graft-versus-host-disease-for-patients-receiving-allogeneic-hematopoietic-stem-cell-transplantation\/"},{"@type":"ListItem","position":3,"name":"Seventure Partners Life Sciences Investing Update &#8211; H2 2017_VF"}]},{"@type":"WebSite","@id":"https:\/\/www.seventure.fr\/en\/#website","url":"https:\/\/www.seventure.fr\/en\/","name":"Seventure","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.seventure.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"description":{"rendered":"<p class=\"attachment\"><a href='https:\/\/www.seventure.fr\/wp-content\/uploads\/2018\/02\/Seventure-Partners-Life-Sciences-Investing-Update-H2-2017_VF.pdf'>Seventure Partners Life Sciences Investing Update - H2 2017_VF<\/a><\/p>\n"},"caption":{"rendered":"<p>Seventure Partners Life Sciences Investing Update &#8211; H2 2017_VF<\/p>\n"},"alt_text":"","media_type":"file","mime_type":"application\/pdf","media_details":{},"post":3435,"source_url":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2018\/02\/Seventure-Partners-Life-Sciences-Investing-Update-H2-2017_VF.pdf","_links":{"self":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/media\/4920","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/media"}],"about":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/types\/attachment"}],"author":[{"embeddable":true,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/comments?post=4920"}]}}